The clinical effects of levosimendan are not attenuated by sulfonylureas

Scandinavian Cardiovascular Journal

Volumn 46, Issue 6, 2012, Pages 330-338

  Kivikko, Matti ^a,b   Nieminen, Markku S ^a   Pollesello, Piero ^b   Pohjanjousi, Pasi ^b   Colucci, Wilson S ^c   Teerlink, John R ^d   Mebazaa, Alexandre ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Acute decompensated heart failure; ATP dependent potassium channels; Diabetes mellitus; Inodilator; Levosimendan; Sulfonylureas

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; LEVOSIMENDAN; PLACEBO; SULFONYLUREA DERIVATIVE; TOLAZAMIDE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG POTENTIATION; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

AGED; DIABETES MELLITUS; DRUG INTERACTIONS; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; HYPOGLYCEMIC AGENTS; KATP CHANNELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84870032573     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2012.725206     Document Type: Article

References (28)

1. Follath F. Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Devel Ther. 2009; 3: 73-8.
2. Usta C, Eksert B, Gölbasi I, Bigat Z, Ozdem S. The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries. Eur J Cardiothorac Surg. 2006; 30: 329-32.
3. Höhn J, Pataricza J, Petri A, Tóth GK, Balogh A, Varró A, Papp JG. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol. 2004; 94: 271-3.
4. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001; 37: 367-74.
5. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, anew positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels. Anesth Analg. 2000; 90: 5-11.
6. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007; 50: 257-63.
7. Murata M, Akao M, O'Rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca (2) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circulation. 2001; 89: 891-8.
8. Burger AJ, Tsao L, Aronson D. Prognostic impact of diabetes mellitus in patients with acute decompensated heart failure. Am J Cardiol. 2005; 95: 1117-9.
9. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27: 2725-36.
10. Lefer DJ, Nichols CG, Coetzee WA. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med. 2009; 19: 61-7.
11. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K (ATP) and BK (Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006; 148: 696-702.
12. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36: 1903-12.
13. Slawsky M T, Colucci W S, Gottlieb S S, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators. Circulation. 2000; 102: 2222-7.
14. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003; 107: 81-6
15. Follath F, Cleland J G, Just H, Papp J G, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360: 196-202.
16. Moiseyev V S, Põd er P, Andrejevs N, Ruda M Y, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Arandomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23: 1422-32.
17. Mebazaa A, Nieminen M S, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs Dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007; 297: 1883-91.
18. de Lissovoy G, Fraeman K, Teerlink J R, Mullahy J, Salon J, Sterz R, et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ. 2010; 11: 185-93.
19. From A M, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006; 119: 591-9.
20. Fisman EZ, Tenenbaum A. Acardiologic approach to noninsulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol. 2009; 8: 38: doi:10.1186/1475-2840-8-38
21. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, J ø rgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010; 53: 2546-53.
22. Sandell E P, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikainen PJ. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol. 1995; 26: S57-62.
23. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002; 40: 465-71.
24. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007; 9: 75-82.
25. Bergh C H, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010; 12: 404-10.
26. Szilágyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004; 486: 67-74.
27. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012; 40: 634-46.
28. Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther. 2011; 33: 408-24.